Literature DB >> 7765388

Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines.

J L Telford1, A Covacci, P Ghiara, C Montecucco, R Rappuoli.   

Abstract

The recognition that peptic ulcer is an infectious disease caused by the bacterium Helicobacter pylori has revolutionized the approach to diagnosis and therapy of this condition. Treatment of the symptoms of peptic ulcer with drugs that block acid secretion is already being replaced by antibiotic eradication of the causative agent. Studies of the molecular events that lead to H. pylori pathogenesis have shown that clinical isolates can be divided into two groups, only one of which produces a cytotoxin and is associated with severe disease. The cloning of the genes coding for molecules specific for disease-associated strains of H. pylori, and the development of animal models that mimic the human pathology, will provide the basis for better strategies to treat and prevent peptic-ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7765388     DOI: 10.1016/0167-7799(94)90031-0

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  27 in total

1.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.

Authors:  J Parsonnet; G D Friedman; N Orentreich; H Vogelman
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Multiplex PCR assay for rapid detection and genotyping of Helicobacter pylori directly from biopsy specimens.

Authors:  Santanu Chattopadhyay; Rajashree Patra; T Ramamurthy; Abhijit Chowdhury; Amal Santra; G K Dhali; S K Bhattacharya; Douglas E Berg; G Balakrish Nair; Asish K Mukhopadhyay
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  The vacuolating toxin from Helicobacter pylori forms hexameric pores in lipid bilayers at low pH.

Authors:  D M Czajkowsky; H Iwamoto; T L Cover; Z Shao
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Effect of Helicobacter pylori on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA.

Authors:  V Ricci; C Ciacci; R Zarrilli; P Sommi; M K Tummuru; C Del Vecchio Blanco; C B Bruni; T L Cover; M J Blaser; M Romano
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

5.  The m2 form of the Helicobacter pylori cytotoxin has cell type-specific vacuolating activity.

Authors:  C Pagliaccia; M de Bernard; P Lupetti; X Ji; D Burroni; T L Cover; E Papini; R Rappuoli; J L Telford; J M Reyrat
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

6.  Outer membrane targeting of passenger proteins by the vacuolating cytotoxin autotransporter of Helicobacter pylori.

Authors:  W Fischer; R Buhrdorf; E Gerland; R Haas
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

7.  Helicobacter pylori upregulates expression of epidermal growth factor-related peptides, but inhibits their proliferative effect in MKN 28 gastric mucosal cells.

Authors:  M Romano; V Ricci; A Di Popolo; P Sommi; C Del Vecchio Blanco; C B Bruni; U Ventura; T L Cover; M J Blaser; R J Coffey; R Zarrilli
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

8.  Genome sequence of a clinical isolate of Campylobacter jejuni from Thailand.

Authors:  Frédéric Poly; Timothy Read; David R Tribble; Shahida Baqar; Maria Lorenzo; Patricia Guerry
Journal:  Infect Immun       Date:  2007-04-16       Impact factor: 3.441

9.  Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies.

Authors:  R Manetti; P Massari; D Burroni; M de Bernard; A Marchini; R Olivieri; E Papini; C Montecucco; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease.

Authors:  P Ghiara; M Marchetti; M J Blaser; M K Tummuru; T L Cover; E D Segal; L S Tompkins; R Rappuoli
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.